Search

Your search keyword '"Herbrecht, Raoul"' showing total 49 results
Start Over Author "Herbrecht, Raoul" Journal clinical infectious diseases
49 results on '"Herbrecht, Raoul"'

1. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America

Author

Patterson, Thomas F, Thompson, George R, Denning, David W, Fishman, Jay A, Hadley, Susan, Herbrecht, Raoul, Kontoyiannis, Dimitrios P, Marr, Kieren A, Morrison, Vicki A, Nguyen, M Hong, Segal, Brahm H, Steinbach, William J, Stevens, David A, Walsh, Thomas J, Wingard, John R, Young, Jo-Anne H, and Bennett, John E

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Rare Diseases, Clinical Research, Management of diseases and conditions, 7.3 Management and decision making, Good Health and Well Being, Amphotericin B, Antifungal Agents, Aspergillosis, Azoles, Echinocandins, Humans, Infectious Disease Medicine, Societies, Medical, United States, aspergillosis, invasive aspergillosis, allergic aspergillosis, chronic aspergillosis, fungal diagnostics, azoles, echniocandins, amphotericin, Biological Sciences, Medical and Health Sciences, Microbiology, Clinical sciences
Abstract

It is important to realize that guidelines cannot always account for individual variation among patients. They are not intended to supplant physician judgment with respect to particular patients or special clinical situations. IDSA considers adherence to these guidelines to be voluntary, with the ultimate determination regarding their application to be made by the physician in the light of each patient's individual circumstances.

Published
2016

2. Executive Summary: Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America

Author

Patterson, Thomas F, Thompson, George R, Denning, David W, Fishman, Jay A, Hadley, Susan, Herbrecht, Raoul, Kontoyiannis, Dimitrios P, Marr, Kieren A, Morrison, Vicki A, Nguyen, M Hong, Segal, Brahm H, Steinbach, William J, Stevens, David A, Walsh, Thomas J, Wingard, John R, Young, Jo-Anne H, and Bennett, John E

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Rare Diseases, Clinical Research, 7.3 Management and decision making, Management of diseases and conditions, Good Health and Well Being, Amphotericin B, Antifungal Agents, Aspergillosis, Azoles, Echinocandins, Humans, Infectious Disease Medicine, Practice Guidelines as Topic, Societies, Medical, United States, aspergillosis, invasive aspergillosis, allergic aspergillosis, chronic aspergillosis, fungal diagnostics, azoles, echniocandins, amphotericin, Biological Sciences, Medical and Health Sciences, Microbiology, Clinical sciences
Abstract

It is important to realize that guidelines cannot always account for individual variation among patients. They are not intended to supplant physician judgment with respect to particular patients or special clinical situations. IDSA considers adherence to these guidelines to be voluntary, with the ultimate determination regarding their application to be made by the physician in the light of each patient's individual circumstances.

Published
2016

3. Application of the 2008 Definitions for Invasive Fungal Diseases to the Trial Comparing Voriconazole Versus Amphotericin B for Therapy of Invasive Aspergillosis: A Collaborative Study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group

Author

Herbrecht, Raoul, Patterson, Thomas F., Slavin, Monica A., Marchetti, Oscar, Maertens, Johan, Johnson, Elizabeth M., Schlamm, Haran T., Donnelly, J. Peter, and Pappas, Peter G.

Published
2015

5. Evaluation of Serum Mucorales Polymerase Chain Reaction (PCR) for the Diagnosis of Mucormycoses: The MODIMUCOR Prospective Trial

Author

Millon, Laurence, primary, Caillot, Denis, additional, Berceanu, Ana, additional, Bretagne, Stéphane, additional, Lanternier, Fanny, additional, Morio, Florent, additional, Letscher-Bru, Valérie, additional, Dalle, Frédéric, additional, Denis, Blandine, additional, Alanio, Alexandre, additional, Boutoille, David, additional, Bougnoux, Marie Elisabeth, additional, Botterel, Françoise, additional, Chouaki, Taieb, additional, Charbonnier, Amandine, additional, Ader, Florence, additional, Dupont, Damien, additional, Bellanger, Anne Pauline, additional, Rocchi, Steffi, additional, Scherer, Emeline, additional, Gbaguidi-Haore, Houssein, additional, and Herbrecht, Raoul, additional

Published
2022
Full Text
View/download PDF

7. A Multìcenter, Double-Blind Trial of a High-Dose Caspofungin Treatment Regimen versus a Standard Caspofungin Treatment Regimen for Adult Patients with Invasive Candidiasis

Author

Betts, Robert F., Nucci, Marcio, Talwar, Deepak, Gareca, Marcelo, Queiroz-Telles, Flavio, Bedimo, Roger J., Herbrecht, Raoul, Ruiz-Palacios, Guillermo, Young, Jo-Anne H., Baddley, John W., Strohmaier, Kim M., Tucker, Kimberly A., Taylor, Arlene F., and Kartsonis, Nicholas A.

Published
2009
Full Text
View/download PDF

9. Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria

Author

Segal, Brahm H., Herbrecht, Raoul, Stevens, David A., Ostrosky-Zeichner, Luis, Sobel, Jack, Viscoli, Claudio, Walsh, Thomas J., Maertens, Johan, Patterson, Thomas F., Perfect, John R., Dupont, Bertrand, Wingard, John R., Calandra, Thierry, Kauffman, Carol A., Graybill, John R., Baden, Lindsey R., Pappas, Peter G., Bennett, John E., Kontoyiannis, Dimitrios P., Cordonnier, Catherine, Viviani, Maria Anna, Bille, Jacques, Almyroudis, Nikolaos G., Wheat, L. Joseph, Graninger, Wolfgang, Bow, Eric J., Holland, Steven M., Kullberg, Bart-Jan, Dismukes, William E., and De Pauw, Ben E.

Published
2008
Full Text
View/download PDF

10. Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group

Author

De Pauw, Ben, Walsh, Thomas J., Donnelly, J. Peter, Stevens, David A., Edwards, John E., Calandra, Thierry, Pappas, Peter G., Maertens, Johan, Lortholary, Olivier, Kauffman, Carol A., Denning, David W., Patterson, Thomas F., Maschmeyer, Georg, Bille, Jacques, Dismukes, William E., Herbrecht, Raoul, Hope, William W., Kibbler, Christopher C., Kullberg, Bart Jan, Marr, Kieren A., Muñoz, Patricia, Odds, Frank C., Perfect, John R., Restrepo, Angela, Ruhnke, Markus, Segal, Brahm H., Sobel, Jack D., Sorrell, Tania C., Viscoli, Claudio, Wingard, John R., Zaoutis, Theoklis, and Bennett, John E.

Published
2008
Full Text
View/download PDF

17. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) consensus group

Author

Pauw, Ben De, Walsh, Thomas J., Donnelly, J. Peter, Stevens, David A., Edwards, John E., Calandra, Thierry, Pappas, Peter G., Maertens, Johan, Lortholary, Olivier, Kauffman, Carol A., Denning, David W., Patterson, Thomas F., Maschmeyer, Georg, Bille, Jacques, Dismukes, William E., Herbrecht, Raoul, Hope, William W., Kibbler, Christopher C., Kullberg, Bart Jan, Marr, Kieren A., Munoz, Patricia, Odds, Frank C., Perfect, John R., Restrepo, Angela, Ruhnke, Markus, Segal, Brahm H., Sobel, Jack D., Sorrell, Tania C., Viscoli, Claudio, Wingard, John R., Zaoutis, Theoklis, and Bennett, John E.

Subjects
Mycoses -- Prognosis, Mycoses -- Research, Cancer -- Research, Cancer -- Care and treatment, Health, Health care industry
Published
2008

19. Comparison of 2 studies of treatment of invasive aspergillosis

Author

Denning, David W., Cornely, Oliver A., Maertens, Johan, Ullmann, Andrew J., Heussel, Claus Peter, and Herbrecht, Raoul

Subjects
Amphotericin B -- Dosage and administration, Aspergillosis -- Risk factors, Aspergillosis -- Development and progression, Aspergillosis -- Drug therapy, Drug therapy -- Comparative analysis, Health, Health care industry
Published
2007

20. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad Trial)

Author

Cornely, Oliver A., Maertens, Johan, Bresnik, Mark, Ebrahimi, Ramin, Ullmann, Andrew J., Bouza, Emilio, Heussel, Claus Peter, Lortholary, Olivier, Rieger, Christina, Boehme, Angelika, Aoun, Mickael, Horst, Heinz-August, Thiebaut, Anne, Ruhnke, Markus, Reichert, Dietmar, Vianelli, Nicola, Krause, Stefan W., Olavarria, Eduardo, and Herbrecht, Raoul

Subjects
Amphotericin B -- Dosage and administration, Amphotericin B -- Research, Aspergillosis -- Care and treatment, Health, Health care industry
Published
2007

21. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts

Author

Segal, Brahm H., Almyroudis, Nikolaos G., Battiwalla, Minoo, Herbrecht, Raoul, Perfect, John R., Walsh, Thomas J., and Wingard, John R.

Subjects
Cancer -- Development and progression, Cancer -- Research, Cancer -- Health aspects, Mycoses -- Prevention, Mycoses -- Care and treatment, Mycoses -- Diagnosis, Organ transplant recipients -- Research, Organ transplant recipients -- Health aspects, Neutropenia -- Research, Neutropenia -- Health aspects, Health, Health care industry
Published
2007

22. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign

Author

Greene, Reginald E., Schlamm, Haran T., Oestmann, Jorg-W., Stark, Paul, Durand, Christine, Lortholary, Olivier, Wingard, John R., Herbrecht, Raoul, Ribaud, Patricia, Patterson, Thomas F., Troke, Peter F., Denning, David W., Bennett, John E., de Pauw, Ben E., and Rubin, Robert H.

Subjects
Aspergillosis -- Diagnosis, Aspergillosis -- Research, Aspergillosis -- Care and treatment, CT imaging -- Usage, Mycoses -- Risk factors, Survival after airplane accidents, shipwrecks, etc. -- Research, Survival after airplane accidents, shipwrecks, etc. -- Health aspects, Health, Health care industry
Published
2007

23. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial

Author

Walsh, Thomas J., Raad, Issam, Patterson, Thomas F., Chandrasekar, Pranatharthi, Donowitz, Gerald R., Graybill, Richard, Greene, Reginald E., Hachem, Ray, Hadley, Susan, Herbrecht, Raoul, Langston, Amelia, Louie, Arnold, Ribaud, Patricia, Segal, Brahm H., Stevens, David A., van Burik, Jo-Anne H., White, Charles S., Corcoran, Gavin, Gogate, Jagadish, Krishna, Gopal, Pedicone, Lisa, Hardalo, Catherine, and Perfect, John R.

Subjects
Aspergillosis -- Care and treatment, Aspergillosis -- Research, Drug therapy -- Patient outcomes, Drug therapy -- Research, Triazoles -- Usage, Triazoles -- Research, Health, Health care industry
Published
2007

25. Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers

Author

Cordonnier, Catherine, Ribaud, Patricia, Herbrecht, Raoul, Milpied, Noel, Valteau-Couanet, Dominique, Morgan, Caroline, and Wade, Amath

Subjects
Aspergillosis -- Risk factors, Hematopoietic stem cells -- Transplantation, Hematopoietic stem cells -- Prognosis, Health, Health care industry
Published
2006

26. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome

Author

Patterson, Thomas F., Boucher, Helen W., Herbrecht, Raoul, Denning, David W., Lortholary, Olivier, Ribaud, Patricia, Rubin, Robert H., Wingard, John R., DePauw, Ben, Schlamm, Haran T., Troke, Peter, and Bennett, John E.

Subjects
Aspergillosis -- Diagnosis, Aspergillosis -- Risk factors, Aspergillosis -- Care and treatment, Amphotericin B -- Research, Amphotericin B -- Comparative analysis, Health, Health care industry
Published
2005

27. Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases

Author

Mouas, Houria, Lutsar, Irja, Dupont, Bertrand, Fain, Olivier, Herbrecht, Raoul, Lescure, Francois-Xavier, and Lortholary, Olivier

Subjects
Bone diseases -- Care and treatment, Aspergillosis -- Care and treatment, Aspergillosis -- Case studies, Aspergillosis -- Causes of, Health, Health care industry
Published
2005

29. Epidemiology and risk factors for gram-positive coccal infections in neutropenia: toward a more targeted antibiotic strategy. (Major Article)

Author

Cordonnier, Catherine, Buzyn, Agnes, Leverger, Guy, Herbrecht, Raoul, Hunault, Mathilde, Leclercq, Roland, and Bastuji-Garin, Sylvia

Subjects
Neutropenia -- Complications, Gram-positive bacteria -- Physiological aspects, Staphylococcal infections -- Research, Staphylococcal infections -- Risk factors, Streptococcal infections -- Research, Streptococcal infections -- Risk factors, Health, Health care industry
Published
2003

32. Liposomal amphotericin B trial marred by conclusions

Author

Wolf, Joshua, Buttery, Jim, Daley, Andrew J., Hanieh, Sarah, Shann, Frank, Starr, Mike, Curtis, Nigel, Cornely, Oliver A., Maetens, Johan, and Herbrecht, Raoul

Subjects
Amphotericin B -- Dosage and administration, Amphotericin B -- Research, Pulmonary aspergillosis -- Drug therapy, Health, Health care industry
Published
2007

33. Halo sign and improved outcome

Author

Verweij, Paul E., van Die, Lya, Donnelly, J. Peter, Greene, Reginald E., Schlamm, Haran T., Oestmann, Jorg-W., Stark, Paul, Durand, Christine, Lortholary, Olivier, Wingard, John R., Herbrecht, Raoul, Ribaud, Patricia, Patterson, Thomas F., Troke, Peter F., Denning, David W., Bennett, John E., De Pauw, Ben E., and Rubin, Robert H.

Subjects
Pulmonary aspergillosis -- Care and treatment, Amphotericin B -- Dosage and administration, Amphotericin B -- Research, Health, Health care industry
Published
2007

34. Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE Trial

Author

Kullberg, Bart Jan, primary, Viscoli, Claudio, additional, Pappas, Peter G, additional, Vazquez, Jose, additional, Ostrosky-Zeichner, Luis, additional, Rotstein, Coleman, additional, Sobel, Jack D, additional, Herbrecht, Raoul, additional, Rahav, Galia, additional, Jaruratanasirikul, Sutep, additional, Chetchotisakd, Ploenchan, additional, Van Wijngaerden, Eric, additional, De Waele, Jan, additional, Lademacher, Christopher, additional, Engelhardt, Marc, additional, Kovanda, Laura, additional, Croos-Dabrera, Rodney, additional, Fredericks, Christine, additional, and Thompson, George R, additional

Published
2018
Full Text
View/download PDF

36. Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt

Author

Anaissie, Elias J., Segal, Brahm H., Graybill, John R., Arndt, Carola, Perfect, John R., Kleinberg, Michael, Pappas, Peter, Benjamin, Danny, Rubin, Robert, Aberg, Judith A., Adderson, Elisabeth E., Adler-Shohet, Felice C., Akan, Hamdi, Akova, Murat, Almyroudis, Nikolaos G., Alexander, Barbara D., Andes, David, Arrieta, Antonio, Baddley, John W., Barron, Michelle A., Belzberg, Howard, Boucher, Helen W., Boyce, Thomas G., Casadevall, Arturo, Chandrasekar, P.H., Cleary, John D., Cordonnier, Catherine, Cornely, Oliver A., Cuenca-Estrella, Manuel, Daly, Jennifer S., Daoura, Nicholas, Denning, David W., dePauw, Ben, Repentigny, Louis de, Dignani, Maria Cecilia, Dismukes, William E., Donnelly, J. Peter, Donowitz, Gerald R., Dupont, Bertrand, Drusano, George, Ellis, Michael, Espinel-Ingroff, Ana, Fishman, Jay A., Fleming, Rhonda, Forrest, Graeme, Ghannoum, Mahmoud, Goldman, Mitchell, Grazziutti, Monica, Greene, John N., Greenberg, Richard N., Gubbins, Paul O., Hadley, Susan, Herbrecht, Raoul, Hiemenz, John W., Hope, William, Hospenthal, Durane R., Husain, Shahid, Ito, James I., Jacobson, Robert M., Johnson, Melissa, Keating, Michael R., Kett, Daniel H., Knapp, Katherine, Kontoyiannis, Dimitrios P., Krcmery, Vladimir C., Larsen, Robert, Laverdiere, Michel, Ljungman, Per, Lortholary, O., Maertens, Johan, Marriott, Debbie, Mattiuzzi, Gloria, McGinnis, Michael R., Morris, Michele, Nucci, Marcio, Odds, Frank C., Pankey, George A., Patterson, Thomas, Pfaller, Mike, Razonable, Raymond R., Reboli, Annette C., Rinaldi, Michael G., Roberts, Glenn D., Tudela, Juan Luis Rodriguez, Rotstein, Coleman, Ruhnke, Markus, Schuster, Mindy, Shoham, Shmuel, Sia, Irene G., Siebel, Nita, Silviera, Fernanda, Singh, Nina, Sobel, Jack, Solomkin, Joseph S., Sorrell, Tania C., Steinbach, William J., Temesgen, Zelalem, Tortorano, AnnaMaria, Vartivarian, Shahe, VerWeij, Paul, Viscoli, Claudio, Viviani, Maria Anna, Walker, Randall C., Wheat, Joseph L., Wiley, Joseph, Williamson, Peter, Wingard, John R., Yu, Victor L., and Zaoutis, Theoklis

Subjects
Clinical trials -- Evaluation, Journalism, Medical -- Evaluation, Health, Health care industry
Published
2006

37. Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE Trial.

Author

Kullberg, Bart Jan, Viscoli, Claudio, Pappas, Peter G, Vazquez, Jose, Ostrosky-Zeichner, Luis, Rotstein, Coleman, Sobel, Jack D, Herbrecht, Raoul, Rahav, Galia, Jaruratanasirikul, Sutep, Chetchotisakd, Ploenchan, Wijngaerden, Eric Van, Waele, Jan De, Lademacher, Christopher, Engelhardt, Marc, Kovanda, Laura, Croos-Dabrera, Rodney, Fredericks, Christine, and Thompson, George R

Subjects
COMPARATIVE studies, CONFIDENCE intervals, GENERIC drug substitution, INTRAVENOUS therapy, ORAL drug administration, PATIENT safety, RANDOMIZED controlled trials, TREATMENT effectiveness, BLIND experiment, CANDIDEMIA, INVASIVE candidiasis, VORICONAZOLE, THERAPEUTICS
Abstract

Background Isavuconazole was compared to caspofungin followed by oral voriconazole in a Phase 3, randomized, double-blind, multinational clinical trial for the primary treatment of patients with candidemia or invasive candidiasis. Methods Adult patients were randomized 1:1 to isavuconazole (200 mg intravenous [IV] three-times-daily [TID] for 2 days, followed by 200 mg IV once-daily [OD]) or caspofungin (70 mg IV OD on day 1, followed by 50 mg IV OD [70 mg in patients > 80 kg]) for a maximum of 56 days. After day 10, patients could switch to oral isavuconazole (isavuconazole arm) or voriconazole (caspofungin arm). Primary efficacy endpoint was successful overall response at the end of IV therapy (EOIVT) in patients with proven infections who received ≥1 dose of study drug (modified-intent-to-treat [mITT] population). The pre-specified noninferiority margin was 15%. Secondary outcomes in the mITT population were successful overall response at 2 weeks after the end of treatment, all-cause mortality at days 14 and 56, and safety. Results Of 450 patients randomized, 400 comprised the mITT population. Baseline characteristics were balanced between groups. Successful overall response at EOIVT was observed in 60.3% of patients in the isavuconazole arm and 71.1% in the caspofungin arm (adjusted difference -10.8, 95% confidence interval -19.9–-1.8). The secondary endpoints, all-cause mortality, and safety were similar between arms. Median time to clearance of the bloodstream was comparable between groups. Conclusions This study did not demonstrate non-inferiority of isavuconazole to caspofungin for primary treatment of invasive candidiasis. Secondary endpoints were similar between both groups. Clinical Trials Registration NCT00413218. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

38. Application of the 2008 Definitions for Invasive Fungal Diseases to the Trial Comparing Voriconazole Versus Amphotericin B for Therapy of Invasive Aspergillosis: A Collaborative Study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group

Author

Herbrecht, Raoul, primary, Patterson, Thomas F., additional, Slavin, Monica A., additional, Marchetti, Oscar, additional, Maertens, Johan, additional, Johnson, Elizabeth M., additional, Schlamm, Haran T., additional, Donnelly, J. Peter, additional, and Pappas, Peter G., additional

Published
2014
Full Text
View/download PDF

39. Mycograb for the treatment of invasive candidiasis

Author

Herbrecht, Raoul, Fohrer, Cecile, Nivoix, Yasmine, and Matthews, Ruth

Subjects
Candidiasis -- Care and treatment, Monoclonal antibodies -- Research, Health, Health care industry
Published
2006

41. Tratamiento de la Aspergilosis: Guías para la práctica clínica de la Sociedad de Enfermedades Infecciosas de los Estados Unidos de América (IDSA)

Author

Walsh, Thomas J., primary, Anaissie, Elias J., additional, Denning, David W., additional, Herbrecht, Raoul, additional, Kontoyiannis, Dimitrios P., additional, Marr, Kieren A., additional, Morrison, Vicki A., additional, Segal, Brahm H, additional, Steinbach, William J., additional, Stevens, David A., additional, van Burik, Jo‐Anne, additional, Wingard, John R., additional, and Patterson, y Thomas F., additional

Published
2008
Full Text
View/download PDF

42. Introduction the Forum Report on Advances in the Design of Antifungal Clinical Trials

Author

Bennett, John E., primary, de Pauw, Ben, additional, Dismukes, William, additional, Galgiani, John, additional, Glauser, Michel, additional, Herbrecht, Raoul, additional, Kauffman, Carol, additional, Lee, Jeannette, additional, Pappas, Peter, additional, Powers, John, additional, Rex, John, additional, Verweij, Paul, additional, Viscoli, Claudio, additional, and Walsh, Thomas, additional

Published
2003
Full Text
View/download PDF

43. International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections

Author

Edwards, Jr., John E., primary, Bodey, Gerald P., additional, Bowden, Raleigh A., additional, Buchner, Thomas, additional, de Pauw, Ben E., additional, Filler, Scott G., additional, Ghannoum, Mahmoud A., additional, Glauser, Michel, additional, Herbrecht, Raoul, additional, Kauffman, Carol A., additional, Kohno, Shigeru, additional, Martino, Pietro, additional, Meunier, Francoise, additional, Mori, Takeshi, additional, Pfaller, Michael A., additional, Rex, John H., additional, Rogers, Thomas R., additional, Rubin, Robert H., additional, Solomkin, Joseph, additional, Viscoli, Claudio, additional, Walsh, Thomas J., additional, and White, Mary, additional

Published
1997
Full Text
View/download PDF

44. Treatment of Invasive Aspergillosis with Posaconazole in Patients Who Are Refractory to or Intolerant of Conventional Therapy: An Externally Controlled Trial.

Author

J. Walsh, Thomas, Raad, Issam, Patterson, Thomas F., Chandrasekar, Pranatharthi, Donowitz, Gerald R., Graybill, Richard, Greene, Reginald E., Hachem, Ray, Hadley, Susan, Herbrecht, Raoul, Langston, Amelia, Louie, Arnold, Ribaud, Patricia, Segal, Brahm H., Stevens, David A., Burik, Jo-Anne H. van, S. White, Charles, Corcoran, Gavin, Gogate, Jagadish, and Krishna, Gopal

Subjects
ASPERGILLOSIS, ANTIFUNGAL agents, INFECTION risk factors, STEM cell transplantation, PHARMACOKINETICS, CELLULAR therapy
Abstract

Background. Invasive aspergillosis is an important cause of morbidity and mortality in immunocompromised patients. Current treatments provide limited benefit. Posaconazole is an extended-spectrum triazole with in vitro and in vivo activity against Aspergillus species. Methods. We investigated the efficacy and safety of posaconazole oral suspension (800 mg/day in divided doses) as monotherapy in an open-label, multicenter study in patients with invasive aspergillosis and other mycoses who were refractory to or intolerant of conventional antifungal therapy. Data from external control cases were collected retrospectively to provide a comparative reference group. Results. Cases of aspergillosis deemed evaluable by a blinded data review committee included 107 posaconazolen recipients and 86 control subjects (modified intent-to-treat population). The populations were similar and balanced with regard to prespecified demographic and disease variables. The overall success rate (i.e., the data review committee-assessed global response at the end of treatment) was 42% for posaconazole recipients and 26% for control subjects (odds ratio, 4.06; 95% confidence interval, 1.50–11.04; P = .006). The differences in response between the modified intent-to-treat treatment groups were preserved across additional, prespecified subsets, including infection site (pulmonary or disseminated), hematological malignancy, hematopoietic stem cell transplantation, baseline neutropenia, and reason for enrollment (patient was refractory to or intolerant of previous antifungal therapy). An exposure-response relationship was suggested by pharmacokinetic analyses. Conclusions. Although the study predates extensive use of echinocandins and voriconazole, these findings demonstrate that posaconazole is an alternative to salvage therapy for patients with invasive aspergillosis who are refractory to or intolerant of previous antifungal therapy. [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

45. Invasive Aspergillosis as an Opportunistic Infection in Nonallografted Patients with Multiple...

Author

Lortholary, Olivier, Ascioglu, Sibel, Moreau, Philippe, Herbrecht, Raoul, Marinus, Ann, Casassus, Philippe, De Pauw, Ben, and Denning, David W.

Subjects
ASPERGILLOSIS, OPPORTUNISTIC infections
Abstract

Discusses the occurrence of invasive aspergillosis (IA) in patients with multiple myeloma who were treated at hematology or oncologic centers in Europe between 1984-1996. Occurrence of IA as a potentially lethal opportunistic infection in intensively treated nonallografted patients (ITNP) with MM; Classification of ITNP with MM as being at-risk patients.

Published
2000

46. Cefepime/Amikacin Versus Ceftazidime/Amikacin as Empirical Therapy for Febrile Episodes in Neutropenic Patients: A Comparative Study.

Author

Cordonnier, Catherine, Herbrecht, Raoul, Pico, Jose Luis, Gardembas, Martine, Delmer, Alain, Delain, Martine, Moreau, Philippe, Ladeb, Saloua, Nalet, Véronique, and Rollin, Christian

Abstract

We conducted a randomized multicenter study to compare the efficacy and safety of two antibiotic regimens (cefepime [2 g b.i.d.] plus amikacin or ceftazidime [2 g t.i.d.] plus amikacin) as first-line therapy for fever in patients with hematologic malignancies and neutropenia. A total of 353 patients were randomized according to a 2:1 (cefepime:ceftazidime) ratio. Two hundred-twelve patients in the cefepime group and 107 in the ceftazidime group (90% of all patients) were evaluable for efficacy. The polymorphonuclear neutrophil count was <100/mm3 on enrollment for 70% of the patients. The mean duration of neutropenia was 26 days. The efficacy in both study arms was comparable, although a trend in favor of cefepime was seen in terms of therapeutic success (response rate, 27% vs. 21% for the ceftazidime group). The overall response rate after glycopeptides were added to the regimens was 60% for the cefepime group and 51% for the ceftazidime group; the bacterial eradication rates were 81% vs. 76%, respectively, and the rates of new bacterial infections were 14% vs. 18%, respectively. We conclude that the combination cefepime/ amikacin is at least as effective as the reference regimen of ceftazidime/amikacin in this setting. [ABSTRACT FROM PUBLISHER]

Published
1997

47. The Safety and Efficacy of Amphotericin B Colloidal Dispersion in the Treatment of Invasive Mycoses.

Author

Oppenheim, Beryl A., Herbrecht, Raoul, and Kusne, Shimon

Abstract

Amphotericin B colloidal dispersion (ABCD), a novel formulation of amphotericin B and cholesteryl sulfate in a 1:1 ratio, was developed to reduce the toxicity of amphotericin B yet retain its antifungal efficacy. In an open-label trial, ABCD at dosages as high as 6 mg/(kg·d) was administered to 168 patients with documented or presumed systemic mycoses. All patients had responded incompletely to at least 7 days' treatment with conventional amphotericin B (CAB), had experienced CAB-induced nephrotoxic effects, had preexisting renal impairment, or had experienced other CABrelated, treatment-limiting toxic effects. The clinical response to ABCD could be evaluated in 97 patients. Complete clinical response or improvement was noted in 48 (49%) of them after a mean treatment duration of 18.5 days. All 168 enrolled patients were evaluated with regard to safety of the treatment. Even at daily doses as high as 6 mglkg, and mean and median cumulative doses of 4.0 g and 2.4 g, respectively, ABCD had little renal toxicity: the mean change in serum level of creatinine from baseline to final value was −0.02 mg/dL. Hypokalemia developed in eight patients (5%). This study provides preliminary evidence that ABCD is effective in treating invasive mycoses and lacks the dose-limiting nephrotoxicity of CAB. [ABSTRACT FROM PUBLISHER]

Published
1995
Full Text
View/download PDF

48. Reply to Denning.

Author

Cornely, Oliver A., Maertens, Johan, Ullmann, Andrew J., Heussel, Claus Peter, and Herbrecht, Raoul

Subjects
LETTERS to the editor, ASPERGILLOSIS
Abstract

A response by O.A. Cornely to a letter to the editor about his article about the randomized study of invasive aspergillosis (IA) is presented.

Published
2007
Full Text
View/download PDF

49. Reply to Wolf et al.

Author

Cornely, Oliver A., Maetens, Johan, and Herbrecht, Raoul

Subjects
LETTERS to the editor, AMPHOTERICIN B
Abstract

A reply by O. A. Cornely and colleagues to a letter to the editor about their article "Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing" in the 2007 issue is presented.

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results